Standalone and Consolidated Unaudited Financial Results for Q1FY27

A dose of life THRU ONLINE FILING August 13, 2026 BSE Ltd. National Stock Exchange India Limited, Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block-G, Dalai Street Bandra Kurla Complex, Bandra - (East). Mumbai 400 023 Mumbai-400051. Scrip Code - 524494 Scrip Code : IPCALAB Dear Sirs Re : Outcome of Board Meeting held on 13th August, 2026 Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith our Standalone and Consolidated Unaudited Financial Results along with its limited review reports by the Company’s Auditors for the 1st Quarter ended 30th June, 2026 of the financial year 2026-27, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai. We are also enclosing herewith a press release issued by the Company in respect of its Q1 FY27 unaudited financial Results. Kindly note that the Board meeting started at 12.00 noon and concluded at 1.30 p.m. Thanking you. Yours faithfully For Ipca Laboratories Limited Flarish P. Kamath Corporate Counsel & Company Secretary Enel: a/a Ipca Laboratories Ltd. www.ipca.com 17::, Kandivli Industrial Estate, Kand-'v (West), Mumbai 400 06/ (Maharashtra), ndia T- 4-91 Y) 67'0 5000 F: -91 77 6210 5005 degd Office: 48, Kandivi Industrial Estate, Kandivli (West), Mumbai 400067 (Maharashtra), ndia I -91 22 6647 4444 I ipta#ipca.com CIN: L24239MI I1949?LCOO?837 Ipca Laboratories Limited Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067 CIN : L24239MH1949PLC007837 Tel:+91 22 6647 4444, E-mail: investors@ipca.com Website : www.ipca.com STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 (? Crores) Sr. Particulars Quarter Ended Year Ended No. June 30, 2026 March 31, 2026 June 30,2025 March 31, 2026 Unaudited Unaudited Unaudited (Note 6) Audited Revenue from operations 2,119.24 1,814.35 1,746.90 7,336.75 Other income 17.42 29.88 25.02 94.64 Total Income (l+ll) 2,136.66 1,844.23 1,771.92 7,431.39 IV Expenses a) Cost of materials consumed 445.76 406.27 395.59 1,568.33 b) Purchases of stock-in-trade 110.75 85.03 84.11 348.51 c) Changes in inventories of finished goods, (16.10) (35.51) (31.81) (60.06) work-in-progress and stock-in-trade d) Employee benefits expense 467.32 413.53 409,91 1,655.90 e) Finance costs 5.04 10.48 12.06 43.51 f) Depreciation and amortisation expense 74.61 70.31 63.13 268.87 g) Other expenses 533.87 513.85 482.18 2,043.78 Total Expenses (IV) 1,621.25 1,463.96 1,415.17 5,868.84 V Profit before exceptional items and tax (lll-IV) 515.41 380.27 356.75 1,562.55 VI Exceptional items : (Income) / expenses (Refer note No.4) 30.42 30.42 VII Profit before tax (V-VI) 515.41 349.85 356.75 1,532.13 VIII Tax Expense -Current tax 130.43 97.24 92.66 405.25 -Short / (Excess) provision of earlier years (0.31) (3.13) (3.13) -Deferred tax liability / (asset) 12.00 (6.55) 2.05 (2.51) IX Profit for the period from continuing operations (VII-VIII) 373.29 262.29 262.04 1,132.52 X Other Comprehensive Income A) Items that will not be reclassified to profit or loss - Actuarial gain/(loss) (18.14) 5.14 (2.30) 4.60 Tax effects thereon 4.46 (1.39) 0.59 (1.25) - Fair value change through Other Comprehensive Income 1.24 1.24 Tax effects thereon B) Items that will be reclassified to profit or loss - Exchange difference in translating the financial statement of foreign operation 0.11 1.36 (0.25) 1.86 Tax effects thereon (0.03) (0.37) 0.07 (0.50) Other Comprehensive Income / (Loss) for the period net of tax (X) (13.60) 5.98 (1.89) 5.95 XI Total Comprehensive Income for the period (IX+X) 359.69 268.27 260.15 1,138.47 XII Paid-up equity share capital (Face value of ? 1/- each) 25.37 25.37 25.37 25.37 XIII Other Equity 7,953.98 XIV Net Worth 7,979.35 XV Earnings per share (of ? 1/- each) (Not annualised): Basic / Dik^jl^®^^(peptional items) ( ? ) ,V~ 14.71 11.54 10.33 45.84 Basic/§i mal items) (t) -o 14.71 10.34 10.33 44.64 -3 aCD [‘i.VoA /go <3 o s^eUAcc.^ .9 Notes: 1 The above unaudited standalone financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors at their meeting held on August 13, 2026, 2 The Statutory Auditors of the Company have carried out Limited Review of the unaudited standalone financial results and have issued an unmodified audit report thereon. 3 The above financial results are prepared in accordance with the Indian Accounting Standards (IND-AS) as prescribed under Section 133 of the Companies Act, 2013 and are in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 (as Amended). 4 Exceptional items: (? crores) Sr. No. Particulars Quarter Ended Year Ended June 30, 2026 March 31, 2026 June 30,2025 March 31,2026 a Impact of new Labour Codes 30.42 30.42 Disclosure on above: a Impact of new Labour Codes On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security. 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to gratuity and leave. The Company assessed the financial implications of these changes which has resulted in increase in gratuity and leave liability arising out of past service cost by ? 30.42 crores for the year ended March 31, 2026. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this amount as “Impact of new Labour Codes" under “Exceptional Item” in the Statement of Profit and Loss for the year ended March 31, 2026. 5 At the meeting of the Board of Directors of the Company held on June 26, 2026, it was resolved to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with the Company, subject to necessary consents/approvals. The appointed date for this amalgamation is April 1, 2026. However, pending consents/approvals, no effect for this amalgamation has been given in the unaudited financial results. 6 The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year 2025-26 and the published year to date unaudited figures upto December 31, 2025, which were subjected to limited review. 7 The Company has only one operating segment viz. 'Pharmaceuticals'. 8 Figures of the previous period have been regrouped to conform to the figures of the current period's classification wherever necessary. By Order of the Board For Ipca Laboratories Limited Premchand Godha Place : Mumbai, Executive Chairman Date : August 13, 2026 (DIN 00012691) CL p/ Al q rOd AcC'Jji N V C & Associates LLP CharteredAccountants 903-904,9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email: nvc@nvc.in LLPIN - ACM-9656 Independent Auditor's Review Report on Standalone Unaudited Financial Results for the quarter ended June 30, 2026, of Ipca Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 (as Amended) The Board of Directors of Ipca Laboratories Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results ("the Statement") of Ipca Laboratories Limited ("the Company") for the quarter ended June 30, 2026, being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time (The Listing Regulations). 2. [Showing first 8,000 characters — download PDF for full document]